UNSPSC 51413213: Avanafil

This classification denotes a cgmp phosphodiesterase inhibitor with the molecular structure C23H26CLN7O3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier, DR5S136IVO chemically known as 5-pyrimidinecarboxamide, 4-(((3-chloro-4-methoxyphenyl)methyl)amino)-2-((2s)-2-(hydroxymethyl)-1-pyrrolidinyl)-n-(2-pyrimidinylmethyl)-, but more commonly known as avanafil, which bears U.S. NIH Compound Identifier 9869929.

European Medicines Agency schedules Avanafil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB34916. The term AVANAFIL is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, volume 19, no. 3, 2005, list 54).

UNSPSC 51413213 Avanafil is a Commodity code covering pharmaceutical preparations, specifically the erectile dysfunction medication avanafil. State and local governments procure medications under this code primarily through fire rescue agencies, health and human services departments, and cooperative purchasing alliances serving multiple jurisdictions. Recent solicitations show that state and local buyers source individual pharmaceutical line items through IFBs, RFPs, and RFIs, often bundling avanafil with other branded or generic medications as part of broader advanced life support, emergency medical services, or pharmacy benefit management programs. The work involves supplying FDA-compliant medications with specified expiration dates, managing cold chain or standard storage logistics, providing Safety Data Sheets per OSHA standards, and meeting accessibility documentation requirements such as VPAT conformance and Section 508 compliance.

Recent opportunities span Florida, Texas, and Minnesota. The City of Tampa Fire Rescue issued an IFB (26P00188) in April 2026 for advanced life support medications—a $40,000 contract bundling four specific medication line items including epinephrine, labetalol, adenosine, and diltiazem, with nine-month minimum expiration and ten-day delivery, featuring a 5 percent SLBE bid discount. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 exploring direct-to-manufacturer prescription programs and vendor capabilities for implementing value-based pharmacy contracts outside traditional PBM and GPO channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) in January 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, with proposals due March 26, 2026, requiring cGMP and DSCSA compliance and pricing evaluation weighted 75 percent on competitiveness with contract effectiveness July 1, 2026.